Comparison of FLASH and Conventional Radiotherapy

Study Finds Different Responses Depending on the Tumor Immune Environment

Yoo Dosol, director of the Department of Radiation Oncology at the Dongnam Institute of Radiological & Medical Sciences, has been recognized for academic achievement for research analyzing the relationship between next-generation radiation therapy and antitumor immune responses.


The Dongnam Institute of Radiological & Medical Sciences said Yoo received the Best Poster Award at the 43rd Annual Meeting of the Korean Society for Radiation Oncology, held on October 16 at KINTEX in Goyang.


The award-winning study was titled "Similar Local Control Effects and Distinct Systemic Responses to FLASH and Conventional Radiotherapy: The Role of Tumor Immune-Priming Capacity." It was a preclinical study comparing the local tumor control effects and systemic antitumor immune responses of the two treatment approaches.


FLASH radiotherapy is a next-generation treatment technology that delivers radiation in less than 0.1 seconds at a dose rate thousands of times higher than that of conventional radiotherapy. Although it has been suggested that the technology may preserve tumor-suppressing effects while reducing damage to normal tissue, its effects on antitumor immune responses and on distant tumors that are not directly irradiated have yet to be fully established.


The research team compared FLASH radiotherapy with conventional radiotherapy using two tumor models with different immunological characteristics. The two approaches produced similar control effects in tumors that were directly irradiated, but responses in distant tumors differed depending on the tumors' immunological characteristics and the method used to enhance immunity.


In particular, in the relatively highly immunogenic CT-26 tumor model, combining conventional radiotherapy with immature dendritic cells significantly suppressed the growth of distant tumors. By contrast, this response was not pronounced in the group treated with FLASH radiotherapy in combination with immature dendritic cells or in the less immunogenic LL2 tumor model.


The team said the findings suggest that, even when FLASH and conventional radiotherapy have similar local tumor control effects, they may differ in their systemic antitumor immune responses, including dendritic cell activation and T-cell immune priming. The findings are significant in showing that, to enhance the effectiveness of radiotherapy, it is necessary to consider not only the physical properties of radiation but also the tumor immune environment and the stages of action of any accompanying immune cell therapy.


The study is also notable for linking the Dongnam Institute of Radiological & Medical Sciences' accumulated research expertise in FLASH radiotherapy with its research capabilities in advanced regenerative medicine and antitumor immune cell therapy. The institute has been designated by the Ministry of Health and Welfare as an institution authorized to provide advanced regenerative medicine services. It conducts research combining radiotherapy with cell and gene therapies, drawing on its cell processing facility and antitumor immune cell therapy research platform.


"This award recognizes the significance of research that has expanded the Dongnam Institute of Radiological & Medical Sciences' accumulated expertise in FLASH radiation technology to encompass systemic antitumor immune responses and immune cell therapy," Yoo said, expressing gratitude to doctoral student Yun Yujeong, who collaborated on the research, and to the institute for its support.


"FLASH radiotherapy is a field in which we must consider not only technology that directly treats tumors but also its potential for use in combination with immune cell therapy," Yoo said. "Through follow-up research, we will clarify the mechanisms of dendritic cell and T-cell immune priming and, in connection with the institute's advanced regenerative medicine infrastructure, establish the clinical evidence needed to apply technologies combining radiotherapy and immune cell therapy."



Jeong Seungpil, president of the Dongnam Institute of Radiological & Medical Sciences, said, "This is a significant achievement made possible by combining the FLASH research technology the institute has developed as a pioneer with its expertise in advanced regenerative medicine." He added, "We will continue to strengthen in-house research support and our physician-scientist development system so that clinicians can turn problems encountered in clinical practice into research and work with young researchers to solve them."

Yoo Dosol, head of the Department of Radiation Oncology at the Dongnam Institute of Radiological & Medical Sciences, and Kim Taehyun, president of the Korean Society for Radiation Oncology.

Yoo Dosol, head of the Department of Radiation Oncology at the Dongnam Institute of Radiological & Medical Sciences, and Kim Taehyun, president of the Korean Society for Radiation Oncology.

View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing